Aptus Pharma

Which are the latest news on Aptus Pharma?

Why is Aptus Pharma Ltd falling/rising?

As of 05-Sep, Aptus Pharma Ltd's stock price is rising to 320.45, reflecting a 1.99% increase. The stock has significantly outperformed the Sensex year-to-date, despite a notable decline in investor participation.

As of 05-Sep, Aptus Pharma Ltd's stock price is rising, currently at 320.45, which reflects an increase of 6.25 or 1.99%. This upward movement can be attributed to several factors. The stock has shown a strong performance over the past month, with a return of +7.82%, significantly outperforming the Sensex, which declined by -2.44% during the same period. Year-to-date, Aptus Pharma has experienced an impressive increase of +372.64%, while the Sensex has fallen by -10.21%. <BR><BR>Additionally, the stock is currently trading close to its 52-week high, just 2.08% away from Rs 327.1. It has also been gaining for the last two days, with a total return of 4.03% in this short period. Furthermore, Aptus Pharma is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.<BR><BR>However, it is important to note that there has been a significant decline in investor participation, with delivery volume dropping by -88.02% compared to the 5-day average. Despite this decrease in participation, the stock remains liquid enough for trading, suggesting that the current rise is supported by existing investor confidence and market conditions.

What does Aptus Pharma do?

Aptus Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 550 Cr. It currently has no reported net sales or profits, a P/E ratio of 117.00, and a debt-equity ratio of 0.26.

Overview: <BR>Aptus Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>No specific details regarding the incorporation year or status changes are available. Additionally, there are no sales or profit reports for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 550 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 117.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.26 <BR>Return on Equity: 19.79% <BR>Price-to-Book: 23.56<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Aptus Pharma?

Aptus Pharma's peers include Shree Ganesh Rem, Bafna Pharma, Zim Laboratories, and others. Bafna Pharma has the highest 1-year return at 198.53%, while Infinium Pharma has the lowest at 0.00%.

Peers: The peers of Aptus Pharma are Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, Kilitch Drugs, Valiant Laborato, Albert David, Jenburkt Pharma, Transchem, Haleos Labs Limi, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shree Ganesh Rem, Albert David, and Jenburkt Pharma, while Average management risk is found at Zim Laboratories, Kilitch Drugs, Transchem, Haleos Labs Limi, and the rest. Below Average management risk is noted at Bafna Pharma., Valiant Laborato, and Infinium Pharma. Growth is rated as Good for Kilitch Drugs, Below Average for Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, Valiant Laborato, Albert David, Jenburkt Pharma, Transchem, Haleos Labs Limi, and Infinium Pharma. <BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 198.53%, while Infinium Pharma has the lowest at 0.00%. Aptus Pharma's 1-year return is not available for comparison. Additionally, Zim Laboratories and Haleos Labs Limi have negative six-month returns.

What is the bonus history of Aptus Pharma?

Aptus Pharma recently announced a 3:2 bonus issue, with an ex-date of May 12, 2026. Shareholders on record by this date will receive 3 additional shares for every 2 shares they currently hold.

Aptus Pharma has a recent bonus issue where they announced a 3:2 bonus. The ex-date for this bonus is set for May 12, 2026. This means that shareholders on record as of this date will receive additional shares in the ratio of 3 shares for every 2 shares they currently hold.